


Image



PATENT APPLICATION

1635
\$

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KJETIL TASKÉN et al

Conf. No.: 4681

Appln. No.: 09/428,458

Group Art Unit: 1635

Filed: October 28, 1999

Examiner: Lacourciere, K.

For: USE OF IMMUNOMODULATING AGENTS

**THIRD INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form which the Examiner may deem material to patentability of the claims of the above-identified application.


A copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication (dated December 3, 2003) from a Foreign Patent Office.

The present Third Supplemental Information Disclosure Statement is being filed after a Final Office Action, but before payment of the Issue Fee, and therefore Applicants are submitting herewith a check for the fee of \$180.00 under 37 C.F.R. § 1.17(p), and a Statement Under 37 C.F.R. § 1.97(e).

The submission of the listed documents is not intended as an admission that any such document constitutes prior art

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 09/428,458

against the claims of the present application. Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.


Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Gordon Kit

Registration No. 30,764

Date: March 3, 2004



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KJETIL TASKÉN et al

Conf. No.: **4681**

Appln. No.: **09/428,458**

Group Art Unit: **1635**

Filed: **October 28, 1999**

Examiner: **Lacourciere, K.**

For: **USE OF IMMUNOMODULATING AGENTS**

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:
That each item of information contained in the Third Supplemental Information Disclosure Statement filed concurrently herewith was first cited in a Communication from a Foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of said Third Supplemental Information Disclosure Statement.

Respectfully submitted,

Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373


CUSTOMER NUMBER

Date: March 3, 2004

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/428,458
Confirmation Number	4681
Filing Date	October 28, 1999
First Named Inventor	Kjetil TASKÉN et al
Art Unit	1635
Examiner Name	Lacourciere, K.
Attorney Docket Number	Q-56244

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Hofmann et al, <i>AIDS</i> , 7:659-664 (1993)	
		Øgreid et al, <i>European J. of Biochem.</i> , 227:1089-1094 (1994)	
		Dostmann et al, <i>J. of Biological Chemistry</i> , 265(18):10484-10491 (1990)	
		Cho-Chung, <i>Antisense Nucleic Acid Drug Dev.</i> , 6(3):234-244 (1996 Fall)	Abstract

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.